|
|
|
|
|
|
|
M T W Thu F |
|
3 September, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Two notes: 1) Our annual list of the most exciting startups in biotech, Endpoints 11, is only three weeks away. Join us on the evening of Sept. 24 in Boston as we unveil the new companies defining the future of medicine. 2) Our Peer Review people column is on a break this week and won't publish tomorrow. |
|
|
|
Kevin Miller |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Nicole DeFeudis
|
Merck CEO Robert Davis has been landing deals “with urgency” over the last few years in an effort to shore up the pipeline ahead of... | |
|
|
|
|
|
|
by Lei Lei Wu
|
AbbVie said its T cell engager etentamig cut the risk of disease progression or death by 60% compared with standard therapies in a Phase 3... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Novartis. 🤝 Pfizer turns over ADC:The New York pharma is giving Medicus Pharma co-development rights to a CD228-targeted antibody-drug conjugate known...
| |
|
|
|
|
|
|
|
|
|
Worldwide made. Thanks for reading.
|
| | |
